Biosketch / Results /

Andrew Talal

Adjunct Associate Professor, Department of Medicine

Contact Info

212/745-4495
Andrew.Talal@nyumc.org


Determinants of Hepatitis C Virus Treatment Completion and Efficacy in Drug Users Assessed by Meta-analysis
Dimova, Rositsa B; Zeremski, Marija; Jacobson, Ira M; Hagan, Holly; Des Jarlais, Don C; Talal, Andrew H. Determinants of Hepatitis C Virus Treatment Completion and Efficacy in Drug Users Assessed by Meta-analysis. Clinical infectious diseases. 2013 Mar;56(6):806-816 (249362)

Absolute and relative contraindications to pegylatedinterferon (PEG-IFN) or ribavirin (RBV) in the US general patient population with chronic Hepatitis C (HCV): Results from US Database of Over 45,000 Patients
Talal, A; LaFleur, J; Hoop, R S; Pandya, P K; Martin, P; Jacobson, I M; Han, J; Korner, E. Absolute and relative contraindications to pegylatedinterferon (PEG-IFN) or ribavirin (RBV) in the US general patient population with chronic Hepatitis C (HCV): Results from US Database of Over 45,000 Patients [Meeting Abstract]. Hepatology. 2012 Oct;56:650A-650A (206142)

Determinants of treatment completion and efficacy in drug users assessed by meta-analysis
Dimova, R B; Zeremski, M; Jacobson, I M; Hagan, H; Des, Jarlais D C; Talal, A. Determinants of treatment completion and efficacy in drug users assessed by meta-analysis [Meeting Abstract]. Hepatology. 2012 Oct;56:657A-657A (207622)

Randomized trial comparing dose reduction and growth factor supplementation for management of hematological side effects in HIV/hepatitis C virus patients receiving pegylated-interferon and ribavirin
Talal, Andrew H; Liu, Ruei-Chi; Zeremski, Marija; Dimova, Rositsa; Dove, Lorna; Pearce, Daniel; Hassanein, Tarek; Doonquah, Leleka; Aboulafia, David; Rodriguez, Jorge; Bonilla, Hector; Galpin, Jeffrey; Aberg, Judy A; Johnston, Barbara; Glesby, Marshall J; Jacobson, Ira M. Randomized trial comparing dose reduction and growth factor supplementation for management of hematological side effects in HIV/hepatitis C virus patients receiving pegylated-interferon and ribavirin. Journal of acquired immune deficiency syndromes. JAIDS. 2011 Nov 01;58(3):261-268 (143759)

CXCL9 and CXCL10 chemokines as predictors of liver fibrosis in a cohort of primarily African-American injection drug users with chronic hepatitis C
Zeremski, Marija; Dimova, Rositsa; Astemborski, Jacquie; Thomas, David L; Talal, Andrew H. CXCL9 and CXCL10 chemokines as predictors of liver fibrosis in a cohort of primarily African-American injection drug users with chronic hepatitis C. Journal of infectious diseases. 2011 Sep 15;204(6):832-836 (143760)